<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">32598518</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1523-4681</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>35</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</Title>
                <ISOAbbreviation>J Bone Miner Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of Osteoclast Differentiation by 1.25-D and the Calcimimetic KP2326 Reveals 1.25-D Resistance in Advanced CKD.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2265-2274</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jbmr.4122</ELocationID>
            <Abstract>
                <AbstractText>Active vitamin D analogs and calcimimetics are the main therapies used for treating secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD). Peripheral blood mononuclear cells of 19 pediatric patients with CKD1-5D and 6 healthy donors (HD) were differentiated into mature osteoclasts with receptor activator of NF-ÎºB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). The effects of single or combined treatment with active vitamin D (1.25-D) and/or calcimimetic KP2326 were evaluated on osteoclastic differentiation and osteoclastic-mediated bone resorption. Although 1.25-D inhibited osteoclastic differentiation, a significant resistance to 1.25-D was observed when glomerular filtration rate decreased. A significant albeit less important inhibitory effect of KP2326 on osteoclastic differentiation was also found both in cells derived from HD and CKD patients, through a putative activation of the Erk pathway. This inhibitory effect was not modified by CKD stage. Combinatorial treatment with 1.25-D and KP2326 did not result in synergistic effects. Last, KP2326 significantly inhibited osteoclast-mediated bone resorption. Both 1.25-D and KP2326 inhibit osteoclastic differentiation, however, to a different extent. There is a progressive resistance to 1.25-D in advanced CKD that is not found with KP2326. KP2326 also inhibits bone resorption. Given that 1.25-D has no effect on osteoclastic resorption activity and that calcimimetics also have direct anabolic effects on osteoblasts, there is an experimental rationale that could favor the use of decreased doses of 1.25-D with low doses of calcimimetics in SHPT in dialysis to improve the underlying osteodystrophy. However, this last point deserves confirmatory clinical studies. Â© 2020 American Society for Bone and Mineral Research.</AbstractText>
                <CopyrightInformation>Â© 2020 American Society for Bone and Mineral Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bernardor</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-1356-1507</Identifier>
                    <AffiliationInfo>
                        <Affiliation>INSERM, UMR 1033, FacultÃ© de MÃ©decine Lyon Est, UniversitÃ© Claude Bernard Lyon 1, Lyon, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre de RÃ©fÃ©rence des Maladies RÃ©nales Rares, HÃ´pital Femme MÃ¨re Enfant, Hospices Civils de Lyon, Bron, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>FacultÃ© de MÃ©decine, UniversitÃ© de Nice Sophia Antipolis, Nice, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flammier</LastName>
                    <ForeName>Sacha</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM, UMR 1033, FacultÃ© de MÃ©decine Lyon Est, UniversitÃ© Claude Bernard Lyon 1, Lyon, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre de RÃ©fÃ©rence des Maladies RÃ©nales Rares, HÃ´pital Femme MÃ¨re Enfant, Hospices Civils de Lyon, Bron, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ranchin</LastName>
                    <ForeName>Bruno</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre de RÃ©fÃ©rence des Maladies RÃ©nales Rares, HÃ´pital Femme MÃ¨re Enfant, Hospices Civils de Lyon, Bron, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaillard</LastName>
                    <ForeName>SÃ©golÃ¨ne</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM CIC 1407, CNRS UMR 5558 and Service de Pharmacotoxicologie Clinique, Hospices Civils de Lyon, Bron, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Platel</LastName>
                    <ForeName>Diane</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM, UMR 1033, FacultÃ© de MÃ©decine Lyon Est, UniversitÃ© Claude Bernard Lyon 1, Lyon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peyruchaud</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM, UMR 1033, FacultÃ© de MÃ©decine Lyon Est, UniversitÃ© Claude Bernard Lyon 1, Lyon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Machuca-Gayet</LastName>
                    <ForeName>Irma</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM, UMR 1033, FacultÃ© de MÃ©decine Lyon Est, UniversitÃ© Claude Bernard Lyon 1, Lyon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bacchetta</LastName>
                    <ForeName>Justine</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM, UMR 1033, FacultÃ© de MÃ©decine Lyon Est, UniversitÃ© Claude Bernard Lyon 1, Lyon, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre de RÃ©fÃ©rence des Maladies RÃ©nales Rares, HÃ´pital Femme MÃ¨re Enfant, Hospices Civils de Lyon, Bron, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre de RÃ©fÃ©rence des Maladies Rares du Calcium et du Phosphate, HÃ´pital Femme MÃ¨re Enfant, Hospices Civils de Lyon, Bron, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>FacultÃ© de MÃ©decine Lyon Est, UniversitÃ© Claude Bernard Lyon 1, Lyon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>Grant nÂ° ANR-15-CE14-0010-01</GrantID>
                    <Agency>ANR grant LYSBONE</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Bone Miner Res</MedlineTA>
            <NlmUniqueID>8610640</NlmUniqueID>
            <ISSNLinking>0884-0431</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CHRONIC KIDNEY DISEASE</Keyword>
            <Keyword MajorTopicYN="N">ETELCALCETIDE</Keyword>
            <Keyword MajorTopicYN="N">OSTEOCLAST</Keyword>
            <Keyword MajorTopicYN="N">SECONDARY HYPERPARATHYROIDISM</Keyword>
            <Keyword MajorTopicYN="N">VITAMIN D</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>01</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">32598518</ArticleId>
            <ArticleId IdType="doi">10.1002/jbmr.4122</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>References</Title>
            <Reference>
                <Citation>Moe SM, DrÃ¼eke T. Improving global outcomes in mineral and bone disorders. Clin J Am Soc Nephrol. 2008;3:S127-30.</Citation>
            </Reference>
            <Reference>
                <Citation>Bacchetta J, Harambat J, Cochat P, et al. The consequences of chronic kidney disease on bone metabolism and growth in children. Nephrol Dial Transplant. 2012;27:3063-71.</Citation>
            </Reference>
            <Reference>
                <Citation>Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol Berl Ger. 2006;21:151-9.</Citation>
            </Reference>
            <Reference>
                <Citation>Bacchetta J, Schmitt CP, Ariceta G, et al. Cinacalcet in pediatric dialysis: a position statement from the ESPN and the CKD-MBD working group of the ERA-EDTA. Nephrol Dial Transplant. 2020;35(1):47-64.</Citation>
            </Reference>
            <Reference>
                <Citation>Shroff R, Wan M, Nagler EV, et al. Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages 2-5 and on dialysis. Nephrol Dial Transplant. 2017;32:1114-27.</Citation>
            </Reference>
            <Reference>
                <Citation>Wesseling-Perry K, Pereira RC, Sahney S, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79:112-9.</Citation>
            </Reference>
            <Reference>
                <Citation>Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters. Kidney Int. 2017;92:26-36.</Citation>
            </Reference>
            <Reference>
                <Citation>Allard L, Demoncheaux N, Machuca-Gayet I, et al. Biphasic effects of vitamin D and FGF23 on human osteoclast biology. Calcif Tissue Int. 2015;97:69-79.</Citation>
            </Reference>
            <Reference>
                <Citation>Pereira RC, Khouzam N, Bowen RE, et al. . CKD induces intrinsic alterations in osteoblast response to 1,25D. 1 Pediatrics. Congress Abstract, American Society of Nephrology, David Geffen School of Medicine at UCLA: Los Angeles; 2015.</Citation>
            </Reference>
            <Reference>
                <Citation>Nemeth EF, Goodman WG. Calcimimetic and calcilytic drugs: feats, flops, and futures. Calcif Tissue Int. 2016;98:341-58.</Citation>
            </Reference>
            <Reference>
                <Citation>Goltzman D, Hendy GN. The calcium-sensing receptor in bone-mechanistic and therapeutic insights. Nat Rev Endocrinol. 2015;11:298-307.</Citation>
            </Reference>
            <Reference>
                <Citation>Dvorak MM, Chen T-H, Orwoll B, et al. Constitutive activity of the osteoblast Ca2+âsensing receptor promotes loss of cancellous bone. Endocrinology. 2007;148:3156-63.</Citation>
            </Reference>
            <Reference>
                <Citation>Mentaverri R, Yano S, Chattopadhyay N, et al. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J. 2006;20:2562-4.</Citation>
            </Reference>
            <Reference>
                <Citation>Nguyen-Yamamoto L, Bolivar I, Strugnell SA, Goltzman D. Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis. J Am Soc Nephrol. 2010;21:1713-23.</Citation>
            </Reference>
            <Reference>
                <Citation>Diepenhorst NA, Leach K, Keller AN, et al. Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity: divergent effects of Sr2+o and calcimimetics on human osteoclasts. Br J Pharmacol. 2018;175(21):4095-108.</Citation>
            </Reference>
            <Reference>
                <Citation>Claramunt-Taberner D, Flammier S, Gaillard S, et al. Bone disease in nephropathic cystinosis is related to cystinosin-induced osteoclastic dysfunction. Nephrol Dial Transplant. 2018;33:1525-32.</Citation>
            </Reference>
            <Reference>
                <Citation>Fielden MR, Dean C, Black K, et al. Nonclinical safety profile of etelcalcetide, a novel peptide calcimimetic for the treatment of secondary hyperparathyroidism. Int J Toxicol. 2016;35:294-308.</Citation>
            </Reference>
            <Reference>
                <Citation>Aref MW, Swallow EA, Metzger CE, et al. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study. Osteoporos Int J. 2019;30:1693-8.</Citation>
            </Reference>
            <Reference>
                <Citation>Alexander ST, Hunter T, Walter S, et al. Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol. 2015;88:853-65.</Citation>
            </Reference>
            <Reference>
                <Citation>FromiguÃ© O, HaÃ¿ E, Barbara A, et al. Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med. 2009;13:2189-99.</Citation>
            </Reference>
            <Reference>
                <Citation>Ko Y-A, Mohtat D, Suzuki M, et al. Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol. 2013;14:R108.</Citation>
            </Reference>
            <Reference>
                <Citation>Chen P, Narayanan A, Wu B, et al. Population pharmacokinetic and pharmacodynamic modeling of etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis. Clin Pharmacokinet. 2018;57:71-85.</Citation>
            </Reference>
            <Reference>
                <Citation>Walter S, Baruch A, Dong J, et al. Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther. 2013;346:229-40.</Citation>
            </Reference>
            <Reference>
                <Citation>Leach K, Gregory KJ. Molecular insights into allosteric modulation of class C G protein-coupled receptors. Pharmacol Res. 2017;116:105-18.</Citation>
            </Reference>
            <Reference>
                <Citation>Godwin SL, Soltoff SP. Calcium-sensing receptor-mediated activation of phospholipase C-gamma1 is downstream of phospholipase C-beta and protein kinase C in MC3T3-E1 osteoblasts. Bone. 2002;30:559-66.</Citation>
            </Reference>
            <Reference>
                <Citation>Huang Z, Cheng SL, Slatopolsky E. Sustained activation of the extracellular signal-regulated kinase pathway is required for extracellular calcium stimulation of human osteoblast proliferation. J Biol Chem. 2001;276:21351-8.</Citation>
            </Reference>
            <Reference>
                <Citation>Lutter A-H, Hempel U, Anderer U, Dieter P. Biphasic influence of PGE2 on the resorption activity of osteoclast-like cells derived from human peripheral blood monocytes and mouse RAW264.7 cells. Prostaglandins Leukot Essent Fatty Acids. 2016;111:1-7.</Citation>
            </Reference>
            <Reference>
                <Citation>Gerbino A, Colella M. The different facets of extracellular calcium sensors: old and new concepts in calcium-sensing receptor signalling and pharmacology. Int J Mol Sci. 2018;19(4):999.</Citation>
            </Reference>
            <Reference>
                <Citation>Cianferotti L, Gomes AR, Fabbri S, et al. The calcium-sensing receptor in bone metabolism: from bench to bedside and back. Osteoporos Int. 2015;26:2055-71.</Citation>
            </Reference>
            <Reference>
                <Citation>DÃ­az-Tocados JM, RodrÃ­guez-Ortiz ME, AlmadÃ©n Y, et al. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int. 2019;95:1064-78.</Citation>
            </Reference>
            <Reference>
                <Citation>Li X, Yu L, Asuncion F, et al. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. Bone. 2017;105:163-72.</Citation>
            </Reference>
            <Reference>
                <Citation>Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc Nephrol. 2018;13:962-9.</Citation>
            </Reference>
            <Reference>
                <Citation>Bacchetta J, Bardet C, PriÃ© D. Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting. Metabolism. 2020;103S:153865.</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>